Guardian Pharmacy Services (GRDN) Q4 FY2024 earnings: revenue $339 million

Guardian Pharmacy Services, Inc. (GRDN) reported revenue of $339 million for Q4 FY2024, the quarter ended 31 December 2024. Net income was $12 million, and diluted earnings per share $0.19. The figures are the company's own, from the 10-K it filed with the SEC on 11 March 2026.

Revenue$339 million

Net income$12 million

Diluted EPS$0.19

QuarterQ4 FY2024ended 31 December 2024

The quarter, against the one before and a year earlier

Line	Q4 FY2024	Q3 FY2024	A year earlier	Change on the year
Revenue	339	314	n/a	n/a
Cost of revenue	271	254	n/a	n/a
Gross profit	67.1	60.9	n/a	n/a
Gross margin	19.8%	19.4%	n/a
Selling, general and administrative	50.3	165	n/a	n/a
Operating income	16.8	-105	n/a	n/a
Operating margin	4.9%	-33.3%	n/a
Interest expense	0.4	1.0	n/a	n/a
Pre-tax income	16.2	-106	n/a	n/a
Income tax	4.4	0.2	n/a	n/a
Effective tax rate	27.0%	n/a	n/a
Net income	11.9	-122	n/a	n/a
Net margin	3.5%	-38.8%	n/a
Diluted EPS	$0.19	-$2.00	n/a	n/a

$ million except per share.

Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

Line	Q4 FY2024	Q3 FY2024	A year earlier	Change on the year
Operating cash flow	22.3	-2.2	n/a	n/a
Capital expenditure	n/a	2.2	n/a	n/a
Free cash flow	n/a	-4.4	n/a	n/a
Free cash flow margin	n/a	-1.4%	n/a
Cash from investing	-6.6	-7.1	n/a	n/a
Cash from financing	-48.3	44.9	n/a	n/a
Depreciation and amortisation	5.2	5.0	n/a	n/a
Share-based compensation	3.5	122	n/a	n/a
Diluted shares, weighted	63m	n/a	n/a	n/a
Shares outstanding at period end	n/a	63m	n/a	n/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

Line	Q4 FY2024	Q3 FY2024	A year earlier	Change on the year
Shareholders' equity	150	134	n/a	n/a
Debt	0.0	44.1	n/a	n/a
Operating lease liabilities	23.3	23.8	n/a	n/a
Finance lease liabilities	3.4	n/a	n/a	n/a
Other liabilities	144	146	n/a	n/a
Total liabilities and equity	321	348	n/a	n/a
Fixed assets	49.9	48.1	n/a	n/a
Goodwill	69.3	68.4	n/a	n/a
Intangible assets	14.9	15.2	n/a	n/a
Cash and equivalents	4.7	37.2	n/a	n/a
Receivables	97.2	90.9	n/a	n/a
Inventory	40.5	45.2	n/a	n/a
Other assets	44.4	43.0	n/a	n/a
Total assets	321	348	n/a	n/a

Questions

What was Guardian Pharmacy Services' revenue in Q4 FY2024?

Guardian Pharmacy Services (GRDN) reported revenue of $339 million for Q4 FY2024, the quarter ended 31 December 2024.

How much did Guardian Pharmacy Services earn in Q4 FY2024?

Net income for Q4 FY2024 was $12 million, and diluted earnings per share $0.19.

When did Guardian Pharmacy Services report Q4 FY2024 results?

Guardian Pharmacy Services filed its 10-K for the year that ended with the quarter on 11 March 2026; the fourth quarter is the year less the first three.

Quarterly results, the last 11 quarters

	Q3 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	263	275	300	314	339	329	344	377	398	337	352
Cost of revenue	211	220	239	254	271	265	276	303	312	260	272
Gross profit	52.2	55.1	61.3	60.9	67.1	64.3	68.1	74.7	85.5	76.3	80.0
Gross margin	20%	20%	20%	19%	20%	20%	20%	20%	22%	23%	23%
SG&A	58.5	47.2	44.3	165	50.3	51.3	55.6	58.4	54.7	58.6	59.4
Operating income	-6.3	7.9	17.0	-105	16.8	13.0	12.6	16.4	30.8	17.7	20.6
Operating margin	-2%	3%	6%	-33%	5%	4%	4%	4%	8%	5%	6%
Interest expense	0.7	0.8	1.1	1.0	0.4	0.2	0.2	0.2	0.2	0.2	0.2
Pre-tax income	-7.0	7.1	15.8	-106	16.2	13.1	12.6	16.6	31.1	18.3	29.8
Tax rate	n/a	0%	0%	n/a	27%	29%	30%	42%	32%	26%	26%
Net income	-7.0	7.1	0.0	-122	11.9	9.4	9.0	9.8	20.9	13.3	21.9
Net margin	-3%	3%	0%	-39%	4%	3%	3%	3%	5%	4%	6%
Diluted EPS	n/a	n/a	n/a	-$2.00	$0.19	$0.15	$0.14	$0.15	$0.33	$0.21	$0.34
Operating cash flow	n/a	8.7	29.1	-2.2	22.3	17.6	19.9	28.2	34.6	6.1	30.0
Capital expenditure	n/a	n/a	n/a	2.2	n/a	n/a	n/a	4.0	n/a	n/a	n/a
Free cash flow	n/a	n/a	n/a	-4.4	n/a	n/a	n/a	24.2	n/a	n/a	n/a
Shares outstanding	n/a	n/a	n/a	63m	n/a	63m	63m	63m	63m	63m	63m
Filing	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2024, filed 11 March 2026: the filing.